Ge Long Hui·2025-08-24 22:41Core Insights - The company reported a revenue of RMB 286.04 billion for the first half of 2025, a decrease of 2.95% compared to the same period last year [1] - Net profit and attributable net profit were RMB 5.34 billion and RMB 3.47 billion, reflecting year-on-year declines of 9.53% and 6.43% respectively [1] Revenue Breakdown - The pharmaceutical distribution segment maintained stable development, with its revenue share decreasing by 0.48 percentage points to 73.62% [1] - The medical device distribution revenue saw a slight decline, with its revenue share increasing by 0.08 percentage points to 19.22% [1] - The pharmaceutical retail segment experienced growth, with its revenue share increasing by 0.36 percentage points to 5.78% [1] Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs, integrated management measures, and lower business costs [1] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, with a total optimization of 0.2 percentage points [1]